View in Other Languages

Prima Biomed Ltd

ASX:PRR ISIN:AU000000PRR9

Prima Biomed (ASX:PRR) is a biotechnology company based in Sydney, Australia. The Company is focused on technologies in the fields of immunology and cancer immunotherapy. Prima is focused on developing a dendritic-cell based immunotherapy targeting mucin-1 tumour expressed antigen. Prima's lead product, CVac(tm) has completed Phase IIa clinical development in Ovarian Cancer and is working to a path of US FDA IND approval.

  

News

Biotech Investors Move Ahead on the Learning Curve

🕔6/11/2015 3:13:43 PM 7016

Australian and New Zealand biotech investors are set to hear from a top line up of speakers from ASX-listed life science companies, as well as several private firms and international businesses, in July, at the 11th Bioshares Biotech Summit.

Read Full Article

Sino Gas And Energy Holdings Limited (ASX:SEH) Secures A$29.4M Funding To Increase Gas Sales

🕔4/27/2011 9:58:00 AM 7151

Sino Gas & Energy Holdings Limited (ASX:SEH), an Australian company developing unconventional gas assets within the Ordos Basin, Shanxi Province China, is pleased to advise that it has signed an agreement to raise up to A$29.4 million in new funds from SpringTree Special Opportunities Fund, LP, a New York-based institutional investor, over the next two years.

Read Full Article

Australian Market Report of February 21, 2011: Prima BioMed (ASX:PRR) To Commence Clinical Trial For Ovarian Cancer Immunotherapy Vaccine

🕔2/21/2011 12:21:54 PM 11027

Australian Market Report of February 21, 2011 includes: Prima BioMed Limited (ASX:PRR) will commence the Phrase III clinical trial for what could be the world's first ovarian cancer immunotherapy vaccine; Redstone Resources Limited (ASX:RDS) announced further high grade copper results at the Tollu copper project in Western Australia; Western Desert Resources Limited (ASX:WDR) reported more high-grade iron ore results at Roper Bar Iron Ore Project in the Northern Territory; Canyon Resources Limited (ASX:CAY) updated on accelerated drilling program in Burkina Faso.

Read Full Article

Prima Biomed (ASX:PRR) Receives GAP Report For Cancer Product Toward US FDA

🕔3/19/2008 2:18:44 PM 6812

Australian cancer treatment development company Prima Biomed (Prima, the Company) (ASX: PRR) is pleased to provide the following update and advances in its cancer treatment technologies and programs.

Read Full Article

PRIMA BIOMED LTD ASX: PRR - Interim Results - Clinical Trial for Ovarian Cancer Drug; Mr Eugene Kopp, Executive Chairman

🕔5/16/2006 2:15:00 PM 3948

PRIMA BIOMED LTD (ASX: PRR) - Interim Results - Clinical Trial for Ovarian Cancer Drug; Mr Eugene Kopp, Executive Chairman; Boardroomradio is pleased to announce that PRIMA BIOMED LTD (ASX: PRR) has p

Read Full Article

PRIMA BIOMED LTD ASX: PRR - Interim Results - Clinical Trial for Ovarian Cancer Drug; Dr George Mihaly, Chair of Scientific Advisory Panel

🕔5/16/2006 2:00:00 PM 3555

PRIMA BIOMED LTD (ASX: PRR) - Interim Results - Clinical Trial for Ovarian Cancer Drug; Dr George Mihaly, Chair of Scientific Advisory Panel; Boardroomradio is pleased to announce that PRIMA BIOMED LT

Read Full Article
###

90,409 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 48) (Last 30 Days: 182) (Since Published: 9687) 

Markets ASX:PRR

Company Data

    Headquarters
  • Suite 1705, 109 Pitt St
    Sydney NSW 2000 AUSTRALIA
  • Telephone
  • +61 2 9232 4420 
  • Fax
  • +61 2 9232 4450 
  • Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Biotechnology 
  • Listed
  • 1988/06/23 
  • Homepage
  • www.primabiomed.com.au

Social Media